Flipping the “switch” on mutant p53 by zinc metallochaperones: how a brief pulse of zinc can reactivate mutant p53 to kill cancer
Flipping the “switch” on mutant p53 by zinc metallochaperones: how a brief pulse of zinc can reactivate mutant p53 to kill cancer |
https://doi.org/10.18632/oncotarget.26561
Xin Yu,
and Darren R. Carpizo
|
918-919 |
Modes of immunosuppression in glioblastoma microenvironment
Modes of immunosuppression in glioblastoma microenvironment |
https://doi.org/10.18632/oncotarget.26643
Suvi Lehtipuro,
Matti Nykter,
and Kirsi J. Granberg
|
920-921 |
Tumor stroma as contributing factor in the lymph node metastases process?
Tumor stroma as contributing factor in the lymph node metastases process? |
https://doi.org/10.18632/oncotarget.26644
Wilma E. Mesker,
Gabi W. van Pelt,
and Rob A.E.M. Tollenaar
|
922-923 |
A hint from zebrafish models of hepatic tumorigenesis: Targeting stearoyl-CoA desaturase
A hint from zebrafish models of hepatic tumorigenesis: Targeting stearoyl-CoA desaturase |
https://doi.org/10.18632/oncotarget.26645
Kunpeng Lv,
Fei Fei,
and Xu Wang
|
924-925 |
Oncofertility counselling in premenopausal women with HER2-positive breast cancer
Oncofertility counselling in premenopausal women with HER2-positive breast cancer |
https://doi.org/10.18632/oncotarget.26565
Matteo Lambertini,
Isabelle Demeestere,
Giulia Viglietti,
and Evandro de Azambuja
|
926-929 |
Recurrent hotspot SF3B1 mutations at codon 625 in vulvovaginal mucosal melanoma identified in a study of 27 Australian mucosal melanomas
Recurrent hotspot SF3B1 mutations at codon 625 in vulvovaginal mucosal melanoma identified in a study of 27 Australian mucosal melanomas |
https://doi.org/10.18632/oncotarget.26584
Camelia Quek,
Robert V. Rawson,
Peter M. Ferguson,
Ping Shang,
Ines Silva,
Robyn P.M. Saw,
Kerwin Shannon,
John F. Thompson,
Nicholas K. Hayward,
Georgina V. Long,
Graham J. Mann,
Richard A. Scolyer,
and James S. Wilmott
|
930-941 |
Results of the extended analysis for cancer treatment (EXACT) trial: a prospective translational study evaluating individualized treatment regimens in oncology
Results of the extended analysis for cancer treatment (EXACT) trial: a prospective translational study evaluating individualized treatment regimens in oncology |
https://doi.org/10.18632/oncotarget.26604
Gerald W. Prager,
Matthias Unseld,
Fredrik Waneck,
Robert Mader,
Fritz Wrba,
Markus Raderer,
Thorsten Fuereder,
Phillip Staber,
Ulrich Jäger,
Markus Kieler,
Daniela Bianconi,
Mir Alireza Hoda,
Lukas Baumann,
Alexander Reinthaller,
Walter Berger,
Christoph Grimm,
Heinz Kölbl,
Maria Sibilia,
Leonhard Muellauer,
and Christoph Zielinski
|
942-952 |
TNFR1 single nucleotide polymorphisms are not associated with cervical HPV-induced pre-malignant lesion but regulate in situ cervical TNFR1 expression
TNFR1 single nucleotide polymorphisms are not associated with cervical HPV-induced pre-malignant lesion but regulate in situ cervical TNFR1 expression |
https://doi.org/10.18632/oncotarget.26627
Natália Pereira da Rocha,
Elyzabeth Avvad-Portari,
Fábio Russomano,
Eric Henrique Roma,
Amanda Chaves Pinto,
Evandro Klumb,
Jacyara Macedo,
Ana Teresa Gomes Fernandes,
and Maria da Glória Bonecini-Almeida
|
953-965 |
Circulating miRNAs as a marker of metastatic disease and prognostic factor in metastatic breast cancer
Circulating miRNAs as a marker of metastatic disease and prognostic factor in metastatic breast cancer |
https://doi.org/10.18632/oncotarget.26629
Chara Papadaki,
Giannis Stoupis,
Leuteris Tsalikis,
Alexia Monastirioti,
Maria Papadaki,
Neofytos Maliotis,
Michalis Stratigos,
Georgios Mastrostamatis,
Dimitrios Mavroudis,
and Sofia Agelaki
|
966-981 |
Immune response characterization of endometrial cancer
Immune response characterization of endometrial cancer |
https://doi.org/10.18632/oncotarget.26630
Yuexin Liu
|
982-992 |
CD248: A therapeutic target in cancer and fibrotic diseases
CD248: A therapeutic target in cancer and fibrotic diseases |
https://doi.org/10.18632/oncotarget.26590
Beverly A. Teicher
|
993-1009 |
Correction: CLCA4 inhibits bladder cancer cell proliferation, migration, and invasion by suppressing the PI3K/AKT pathway
Correction: CLCA4 inhibits bladder cancer cell proliferation, migration, and invasion by suppressing the PI3K/AKT pathway |
https://doi.org/10.18632/oncotarget.26656
Teng Hou,
Lijie Zhou,
Longwang Wang,
Gallina Kazobinka,
Xiaoping Zhang,
and Zhaohui Chen
|
1010-1010 |
Erratum: Ocular toxicities associated with targeted anticancer agents: an analysis of clinical data with management suggestions
Erratum: Ocular toxicities associated with targeted anticancer agents: an analysis of clinical data with management suggestions |
https://doi.org/10.18632/oncotarget.26658
Chen Fu,
Dan S. Gombos,
Jared Lee,
Goldy C. George,
Kenneth Hess,
Andrew Whyte,
and David S. Hong
|
1011-1013 |